Wall Street brokerages expect that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will report $78.08 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Pacira Pharmaceuticals’ earnings. The lowest sales estimate is $74.70 million and the highest is $79.42 million. Pacira Pharmaceuticals posted sales of $72.90 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.1%. The business is expected to announce its next earnings report on Wednesday, March 7th.

On average, analysts expect that Pacira Pharmaceuticals will report full year sales of $78.08 million for the current year, with estimates ranging from $281.60 million to $286.65 million. For the next financial year, analysts expect that the business will report sales of $328.41 million per share, with estimates ranging from $311.89 million to $357.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter in the previous year, the company earned $0.20 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis.

PCRX has been the subject of a number of research reports. Jefferies Group cut their target price on shares of Pacira Pharmaceuticals to $52.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. ValuEngine raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Canaccord Genuity set a $42.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 29th. Piper Jaffray Companies reissued a “buy” rating and set a $55.00 target price on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. Finally, Wedbush reissued an “outperform” rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average target price of $49.00.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld acquired 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average price of $41.60 per share, with a total value of $41,600.00. Following the purchase, the director now owns 6,795 shares in the company, valued at $282,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James B. Jones sold 850 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 98,960 shares of company stock valued at $3,868,341. 6.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oppenheimer Asset Management Inc. purchased a new stake in Pacira Pharmaceuticals during the 2nd quarter valued at about $114,000. Cubist Systematic Strategies LLC grew its stake in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after acquiring an additional 1,752 shares in the last quarter. QS Investors LLC purchased a new stake in Pacira Pharmaceuticals during the 2nd quarter valued at about $157,000. Ameritas Investment Partners Inc. grew its stake in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after acquiring an additional 302 shares in the last quarter. Finally, Spectrum Management Group Inc. purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter valued at about $166,000.

Pacira Pharmaceuticals (PCRX) traded down $0.72 on Monday, reaching $41.50. 1,031,800 shares of the company’s stock were exchanged, compared to its average volume of 995,789. Pacira Pharmaceuticals has a one year low of $29.81 and a one year high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $1,680.00, a PE ratio of -31.68 and a beta of 2.20.

COPYRIGHT VIOLATION NOTICE: “$78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/15/78-08-million-in-sales-expected-for-pacira-pharmaceuticals-inc-pcrx-this-quarter.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.